Related Experiment Video

Updated: May 28, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Periostin: a putative mediator involved in tumour resistance to anti-angiogenic therapy?

Wei Wang1, Jin-Liang Ma, Wei-Dong Jia

  • 1Center for the Study of Liver Cancer and Department of Hepatic Surgery, Anhui Provincial Hospital, Anhui Medical University, Hefei, Peoples Republic of China. whouwei@sina.com

Cell Biology International
|October 18, 2011
PubMed

Insights

Periostin, a protein produced by cancer-associated fibroblasts under hypoxia, may drive resistance to anti-angiogenic cancer therapies. Understanding this mechanism could improve treatment outcomes by overcoming drug resistance.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Medicine

Background:

  • Anti-angiogenic therapies show limited survival benefits in cancer patients, largely due to acquired drug resistance.
  • Tumor hypoxia, a common response to anti-angiogenic treatment, triggers adaptive mechanisms that promote resistance.
  • Periostin, an extracellular matrix protein secreted by cancer-associated fibroblasts under hypoxic stress, is implicated in tumor progression.

Purpose of the Study:

  • To investigate the hypothesis that periostin is a key mediator of tumor resistance to anti-angiogenic therapy.
  • To explore the role of periostin in enabling tumors to evade treatment targeting their blood supply.

Main Methods:

  • This study proposes a hypothesis based on indirect evidence and suggests further experimental testing.
  • Evidence reviewed includes periostin's role in promoting tumor angiogenesis, enhancing cancer cell survival under hypoxia, and inducing epithelial-mesenchymal transition (EMT).

Main Results:

  • High periostin levels are associated with increased tumor angiogenesis.
  • Periostin enhances cancer cell survival in hypoxic environments.
  • Modulation of periostin expression influences cancer cell invasion and metastasis, suggesting an escape mechanism.

Conclusions:

  • Periostin is hypothesized to be a critical factor in mediating resistance to anti-angiogenic cancer therapies.
  • Further research confirming periostin's role will elucidate resistance mechanisms.
  • This understanding may provide a basis for improving the efficacy of anti-angiogenic treatments.

More Related Videos

Development of Compendium for Esophageal Squamous Cell Carcinoma03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...